A New Wave of Progress in the Treatment of Renal Cell Carcinoma: Highlights from ASCO GU 2023 and Beyond : Episode 4
Video
Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC
Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.
Related Videos
Related Content
